Pfizer Financial Statements From 2010 to 2024

PFE Stock  USD 26.00  0.61  2.40%   
Pfizer financial statements provide useful quarterly and yearly information to potential Pfizer Inc investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Pfizer financial statements helps investors assess Pfizer's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Pfizer's valuation are summarized below:
Gross Profit
66.2 B
Profit Margin
0.0362
Market Capitalization
145.5 B
Enterprise Value Revenue
3.4975
Revenue
58.5 B
There are over one hundred nineteen available trending fundamental ratios for Pfizer Inc, which can be analyzed over time and compared to other ratios. Investors should ensure to check out all of Pfizer's recent performance against the performance from 2010 to 2024 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 229.8 B. The current year's Enterprise Value is expected to grow to about 240.8 B

Pfizer Total Revenue

39.48 Billion

Check Pfizer financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pfizer main balance sheet or income statement drivers, such as Depreciation And Amortization of 6.6 B, Interest Expense of 2.5 B or Total Revenue of 39.5 B, as well as many exotic indicators such as Price To Sales Ratio of 4.62, Dividend Yield of 0.0598 or PTB Ratio of 1.73. Pfizer financial statements analysis is a perfect complement when working with Pfizer Valuation or Volatility modules.
  
This module can also supplement Pfizer's financial leverage analysis and stock options assessment as well as various Pfizer Technical models . Check out the analysis of Pfizer Correlation against competitors.

Pfizer Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets237.8 B226.5 B170.3 B
Slightly volatile
Short and Long Term Debt Total78.8 B75 B42.1 B
Slightly volatile
Other Current Liabilities28.9 B27.5 B15.7 B
Slightly volatile
Total Current Liabilities50.2 B47.8 B31.4 B
Slightly volatile
Total Stockholder Equity46.9 B89 B67.2 B
Slightly volatile
Property Plant And Equipment Net11.3 B18.9 B13.4 B
Slightly volatile
Net Debt75.8 B72.2 B39.4 B
Slightly volatile
Retained Earnings124.3 B118.4 B82 B
Slightly volatile
CashB2.9 B2.6 B
Slightly volatile
Non Current Assets Total192.3 B183.2 B125.2 B
Slightly volatile
Non Currrent Assets Other5.3 B9.1 BB
Slightly volatile
Cash And Short Term Investments14.9 B12.7 B20.8 B
Pretty Stable
Net Receivables8.7 B11.2 B12.1 B
Very volatile
Common Stock Shares OutstandingB5.7 B3.6 B
Slightly volatile
Liabilities And Stockholders Equity237.8 B226.5 B170.3 B
Slightly volatile
Non Current Liabilities Total93.9 B89.4 B68.3 B
Slightly volatile
Inventory5.2 B10.2 B7.1 B
Slightly volatile
Other Current Assets9.7 B9.3 B3.3 B
Slightly volatile
Total Liabilities144.1 B137.2 B99.7 B
Slightly volatile
Property Plant And Equipment Gross36.7 B35 B19.1 B
Slightly volatile
Total Current Assets32.2 B43.3 B44.2 B
Very volatile
Short Term Debt5.7 B10.9 B6.8 B
Pretty Stable
Intangible Assets68.1 B64.9 B41.1 B
Slightly volatile
Property Plant Equipment11.3 B18.9 B13.4 B
Slightly volatile
Accounts PayableB6.7 B4.5 B
Slightly volatile
Common Stock Total Equity474 M478 M446.9 M
Slightly volatile
Short Term Investments9.3 B9.8 B18.2 B
Pretty Stable
Capital Stock474 M478 M446.9 M
Slightly volatile
Common Stock474 M478 M446.9 M
Slightly volatile
Other Liabilities22.1 B26.9 B26.4 B
Pretty Stable
Other AssetsB6.7 B4.9 B
Slightly volatile
Long Term Debt63.5 B60.5 B34.8 B
Slightly volatile
Good Will40.7 B67.8 B47 B
Slightly volatile
Current Deferred Revenue3.9 B2.7 B4.2 B
Very volatile
Preferred Stock Total Equity14.5 M15.3 M36.9 M
Slightly volatile
Noncontrolling Interest In Consolidated Entity265.1 M274 M318.9 M
Slightly volatile
Retained Earnings Total Equity87 B118.4 B82 B
Slightly volatile
Long Term Debt Total39.6 B61.5 B36.1 B
Slightly volatile
Capital Surpluse90 B92.6 B83.1 B
Slightly volatile
Deferred Long Term Liabilities608 M640 M12.5 B
Slightly volatile
Long Term Investments15.1 B15.4 B14.1 B
Pretty Stable
Non Current Liabilities Other17.2 B16.5 B21.2 B
Pretty Stable
Short and Long Term Debt7.8 B10.3 BB
Slightly volatile
Cash And Equivalents1.8 B2.9 BB
Slightly volatile
Net Invested Capital132 B159.9 B117.9 B
Slightly volatile

Pfizer Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization6.6 B6.3 B4.3 B
Slightly volatile
Total Revenue39.5 B58.5 B54.2 B
Slightly volatile
Gross Profit30.4 B29.3 B39.9 B
Pretty Stable
Other Operating Expenses28.8 B54.3 B39.7 B
Slightly volatile
Operating IncomeB4.2 B14.8 B
Pretty Stable
EBITB4.2 B15.8 B
Very volatile
EBITDA15.4 B10.5 B20.4 B
Pretty Stable
Cost Of Revenue30.7 B29.2 B15.7 B
Slightly volatile
Total Operating Expenses19.8 B25 B25.4 B
Pretty Stable
Income Before TaxB1.1 B12.1 B
Pretty Stable
Net IncomeB2.1 B12.2 B
Pretty Stable
Selling General Administrative13.8 B14.8 B13.3 B
Pretty Stable
Research Development8.2 B10.6 B8.5 B
Slightly volatile
Net Income Applicable To Common Shares37.9 B36.1 B17.3 B
Slightly volatile
Net Income From Continuing Ops2.1 B2.2 B11.7 B
Pretty Stable
Non Recurring1.3 B2.1 B1.5 B
Slightly volatile
Interest Income924.4 M1.6 B1.1 B
Slightly volatile
Reconciled Depreciation4.2 B6.3 B5.7 B
Slightly volatile
Selling And Marketing Expenses2.4 B3.2 B2.4 B
Slightly volatile

Pfizer Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Free Cash Flow4.6 B4.8 B13.9 B
Very volatile
Begin Period Cash Flow395.2 M416 M2.4 B
Slightly volatile
Depreciation4.1 B6.3 B5.6 B
Very volatile
Capital Expenditures4.1 B3.9 B2.2 B
Slightly volatile
Total Cash From Operating Activities12.4 B8.7 B16.4 B
Pretty Stable
Net IncomeB2.1 B12.3 B
Pretty Stable
End Period Cash Flow2.2 B2.9 B2.6 B
Slightly volatile
Stock Based Compensation551.2 M525 M656 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.622.77733.6087
Slightly volatile
Dividend Yield0.05980.05690.0383
Slightly volatile
PTB Ratio1.731.82512.8218
Pretty Stable
Days Sales Outstanding88.1169.741682.7318
Slightly volatile
Book Value Per Share16.5615.774211.565
Slightly volatile
Free Cash Flow Yield0.04450.02950.0676
Pretty Stable
Invested Capital0.850.81350.5731
Slightly volatile
Operating Cash Flow Per Share1.431.54172.6386
Slightly volatile
Stock Based Compensation To Revenue0.00940.0090.0119
Slightly volatile
PB Ratio1.731.82512.8218
Pretty Stable
EV To Sales3.664.01144.1588
Slightly volatile
Free Cash Flow Per Share1.210.84942.2906
Pretty Stable
ROIC0.05120.05390.1305
Very volatile
Inventory Turnover3.012.86712.004
Slightly volatile
Net Income Per Share0.360.37552.0178
Pretty Stable
Days Of Inventory On Hand121127209
Slightly volatile
Payables Turnover2.64.35373.2751
Very volatile
Sales General And Administrative To Revenue0.120.10840.2227
Slightly volatile
Research And Ddevelopement To Revenue0.130.18080.1539
Pretty Stable
Cash Per Share1.672.24883.274
Very volatile
POCF Ratio22.1318.673813.5252
Slightly volatile
Interest Coverage1.71.787711.584
Very volatile
Payout Ratio4.584.36391.1359
Slightly volatile
PFCF Ratio41.5433.895720.0303
Very volatile
Days Payables Outstanding13683.8377122
Very volatile
Income Quality4.284.07881.7876
Slightly volatile
ROE0.02260.02380.1765
Pretty Stable
EV To Operating Cash Flow24.0226.971316.0301
Slightly volatile
PE Ratio80.576.669225.3231
Slightly volatile
Return On Tangible Assets0.02150.02260.1524
Very volatile
EV To Free Cash Flow44.448.956823.5254
Pretty Stable
Earnings Yield0.01240.0130.0609
Slightly volatile
Intangibles To Total Assets0.620.58580.497
Slightly volatile
Net Debt To EBITDA7.26.85872.3282
Slightly volatile
Current Ratio1.740.90671.6454
Slightly volatile
Receivables Turnover3.785.23364.6344
Pretty Stable
Graham Number10.511.544521.4596
Slightly volatile
Shareholders Equity Per Share16.5615.774211.565
Slightly volatile
Debt To Equity0.850.81350.5731
Slightly volatile
Revenue Per Share10.8810.36619.1947
Slightly volatile
Interest Debt Per Share13.9213.25257.1716
Slightly volatile
Debt To Assets0.160.31970.2238
Slightly volatile
Enterprise Value Over EBITDA14.9922.294512.2419
Slightly volatile
Short Term Coverage Ratios0.760.79993.524
Pretty Stable
Price Earnings Ratio80.576.669225.3231
Slightly volatile
Operating Cycle359197302
Pretty Stable
Price Book Value Ratio1.731.82512.8218
Pretty Stable
Days Of Payables Outstanding13683.8377122
Very volatile
Dividend Payout Ratio4.584.36391.1359
Slightly volatile
Price To Operating Cash Flows Ratio22.1318.673813.5252
Slightly volatile
Price To Free Cash Flows Ratio41.5433.895720.0303
Very volatile
Pretax Profit Margin0.01720.01810.2108
Pretty Stable
Ebt Per Ebit0.240.24980.7605
Slightly volatile
Operating Profit Margin0.06880.07240.2566
Slightly volatile
Company Equity Multiplier1.712.54462.3253
Very volatile
Long Term Debt To Capitalization0.430.40870.313
Slightly volatile
Total Debt To Capitalization0.240.44860.3411
Pretty Stable
Return On Capital Employed0.02250.02370.1182
Pretty Stable
Debt Equity Ratio0.850.81350.5731
Slightly volatile
Ebit Per Revenue0.06880.07240.2566
Slightly volatile
Quick Ratio0.850.49941.1802
Slightly volatile
Net Income Per E B T2.12.00281.1251
Slightly volatile
Cash Ratio0.05670.05970.1153
Slightly volatile
Cash Conversion Cycle108113177
Slightly volatile
Operating Cash Flow Sales Ratio0.20.14870.2816
Very volatile
Days Of Inventory Outstanding121127209
Slightly volatile
Days Of Sales Outstanding88.1169.741682.7318
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.580.55090.8002
Very volatile
Cash Flow Coverage Ratios0.110.12010.4261
Very volatile
Price To Book Ratio1.731.82512.8218
Pretty Stable
Fixed Asset Turnover2.72.67543.9098
Very volatile
Price Cash Flow Ratio22.1318.673813.5252
Slightly volatile
Enterprise Value Multiple14.9922.294512.2419
Slightly volatile
Debt Ratio0.160.31970.2238
Slightly volatile
Cash Flow To Debt Ratio0.110.12010.4261
Very volatile
Price Sales Ratio4.622.77733.6087
Slightly volatile
Return On Assets0.00890.00940.0775
Pretty Stable
Asset Turnover0.250.25830.3639
Slightly volatile
Net Profit Margin0.03440.03620.2119
Pretty Stable
Gross Profit Margin0.620.50060.7329
Slightly volatile
Price Fair Value1.731.82512.8218
Pretty Stable
Return On Equity0.02260.02380.1765
Pretty Stable

Pfizer Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap229.8 B218.8 B225.1 B
Slightly volatile
Enterprise Value240.8 B229.3 B235.9 B
Slightly volatile

Pfizer Fundamental Market Drivers

Forward Price Earnings11.6686
Cash And Short Term Investments12.7 B

Pfizer Upcoming Events

7th of May 2024
Upcoming Quarterly Report
View
6th of August 2024
Next Financial Report
View
31st of March 2024
Next Fiscal Quarter End
View
4th of February 2025
Next Fiscal Year End
View
31st of December 2023
Last Quarter Report
View
31st of December 2023
Last Financial Announcement
View

About Pfizer Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Pfizer income statement, its balance sheet, and the statement of cash flows. Pfizer investors use historical funamental indicators, such as Pfizer's revenue or net income, to determine how well the company is positioned to perform in the future. Although Pfizer investors may use each financial statement separately, they are all related. The changes in Pfizer's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Pfizer's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Pfizer Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Pfizer. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2.7 B3.9 B
Total Revenue58.5 B39.5 B
Cost Of Revenue29.2 B30.7 B
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.11  0.12 
Research And Ddevelopement To Revenue 0.18  0.13 
Capex To Revenue(0.07)(0.07)
Revenue Per Share 10.37  10.88 
Ebit Per Revenue 0.07  0.07 

Pfizer Investors Sentiment

The influence of Pfizer's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Pfizer. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Pfizer's public news can be used to forecast risks associated with an investment in Pfizer. The trend in average sentiment can be used to explain how an investor holding Pfizer can time the market purely based on public headlines and social activities around Pfizer Inc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Pfizer's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Pfizer's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Pfizer's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Pfizer.

Pfizer Implied Volatility

    
  85.89  
Pfizer's implied volatility exposes the market's sentiment of Pfizer Inc stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Pfizer's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Pfizer stock will not fluctuate a lot when Pfizer's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Pfizer in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Pfizer's short interest history, or implied volatility extrapolated from Pfizer options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:
Check out the analysis of Pfizer Correlation against competitors.
Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Complementary Tools for Pfizer Stock analysis

When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Global Correlations
Find global opportunities by holding instruments from different markets
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.76)
Dividend Share
1.64
Earnings Share
0.37
Revenue Per Share
10.366
Quarterly Revenue Growth
(0.41)
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.